Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 3;11(4):947–961. doi: 10.1002/jcsm.12565

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Enriched pathways of the differentially expressed secretome genes. (A) Top‐ranked combined scores for The Kyoto Encyclopedia of Genes and Genomes pathway categories associated with upregulated (right panel) and downregulated (left panel) genes in tumour tissues vs. corresponding matched normal tissues of The Cancer Genome Atlas (TCGA) and Genotype‐Tissue Expression (GTEx), computed by the gene set enrichment analysis tool EnrichR.36, 37 Pathways were included in the analysis when satisfying the criteria of over‐representation (log2 combined score > 2) in, at least, one tumour type (colour intensity codes for combined score). Rows and columns were clustered based on Euclidean distance between log2 combined score values. (B) Right: Top‐ranked combined scores for Gene Ontology categories associated with upregulated genes in tumour tissues vs. corresponding matched normal TCGA and GTEx tissues, computed by the gene set enrichment analysis tool EnrichR.36, 37 Left: alluvial diagram connecting the cachexia‐inducing factors predicted into those biological processes terms. BRCA, breast invasive carcinoma; COAD, colon adenocarcinoma; ESCA, oesophageal carcinoma; HNSC, head and neck squamous cell carcinoma; LAML, acute myeloid leukaemia; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; STAD, stomach adenocarcinoma.